befotertinib
2024-0190
Phase 2 small_molecule active
Quick answer
befotertinib for NSCLC (Non-small Cell Lung Cancer) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- NSCLC (Non-small Cell Lung Cancer)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active